Bellevue Healthcare Trust plc (BBH) Ord GBP0.01
Sell:123.80p
Buy:124.20p
0
Change:
1.80p
(1.43%)
1.80p
(1.43%)
FTSE 250:0.25%
Market closed |
Prices as at close on 28 March 2025
Prices delayed by at least 15 minutes
|
Switch to live prices
|
- Add to watchlist
- Create an alert
- This stock can be held in a
Sell:123.80p
Buy:124.20p
Change:
1.80p
(1.43%)
1.80p
(1.43%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Market closed |
Prices as at close on 28 March 2025
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Sell:123.80p
Buy:124.20p
Change:
1.80p
(1.43%)
1.80p
(1.43%)
Market closed |
Prices as at close on 28 March 2025
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Objective
The investment objective of Bellevue Healthcare Trust plc ("the Company") is to provide Shareholders with capital growth and income over the long term, through investment in listed or quoted global healthcare companies. The Company's specific return objectives are: (i) to beat the total return of the MSCI World Healthcare Index (in sterling) on a rolling 3 year period (the index total return including dividends reinvested on a net basis); and (ii) to seek to generate a double-digit total Shareholder return per annum over a rolling 3 year period.
| Security | Weight |
|---|---|
| CareDx Inc | 7.58% |
| Tandem Diabetes Care Inc | 6.63% |
| UnitedHealth Group Inc | 6.42% |
| Bio-Rad Laboratories Inc Class A | 5.74% |
| Charles River Laboratories International Inc | 5.35% |
| Evolent Health Inc Class A | 5.28% |
| Axsome Therapeutics Inc | 5.21% |
| Exact Sciences Corp | 5.05% |
| Option Care Health Inc | 5.02% |
| Insmed Inc | 4.74% |
| Sector | Weight |
|---|---|
| Healthcare | 100.00% |
| Country | Weight |
|---|---|
| United States | 95.29% |
| United Kingdom | 2.94% |
| Hong Kong | 1.55% |
| China | 0.23% |
Fee Structure
Management fee payable monthly in arrear and is at the rate of one-twelfth of 0.95% per calendar month of the Market Capitalisation.There is no performance fee payable to Bellevue. The agreement is terminable on 12 months notice.
Dividend Policy
The Company will set a target dividend each financial year equal to 3.5% of NAV as at the last day of the preceding financial year of the Company. The Company intends to pay dividends on a semi-annual basis, by way of two equal dividends, with dividends declared in July and February/March and paid in August and March/ April in each year. For the financial year 2025, the Board is proposing a total dividend of 5.40p per Ordinary Share.
ASSET SPLIT
Trust Manager
Paul Major
Manager Bio
Paul has 18 years of experience in the healthcare sector on the sell-side and was top-rated by a number of institutional investment clients. He was one of the first research partners at Redburn, Europe’s leading independent research firm. His work there included bespoke projects on healthcare portfolio construction for several institutions. Paul was previously an analyst and corporate financier at UBS Warburg and studied biochemistry.
Board Of Directors
Randeep Singh GrewalChairman, Paul Southgate, Josephine Dixon, Katherine Bolsover, Sarah MacAulay, Clare Brady, Antony Young
Data policy - All information should be used for indicative purposes only. You should
independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete,
and accepts no responsibility for how it may be used.
Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.